Novacyt (NCYT) Competitors GBX 41.93 +0.78 (+1.89%) As of 07/25/2025 11:43 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesBuy This Stock NCYT vs. CREO, IUG, IHC, POLX, AVO, RUA, MHC, SUN, MXCT, and BELLShould you be buying Novacyt stock or one of its competitors? The main competitors of Novacyt include Creo Medical Group (CREO), Intelligent Ultrasound Group (IUG), Inspiration Healthcare Group (IHC), Polarean Imaging (POLX), Advanced Oncotherapy (AVO), RUA Life Sciences (RUA), MyHealthChecked (MHC), Surgical Innovations Group (SUN), MaxCyte (MXCT), and Belluscura (BELL). These companies are all part of the "medical devices" industry. Novacyt vs. Its Competitors Creo Medical Group Intelligent Ultrasound Group Inspiration Healthcare Group Polarean Imaging Advanced Oncotherapy RUA Life Sciences MyHealthChecked Surgical Innovations Group MaxCyte Belluscura Creo Medical Group (LON:CREO) and Novacyt (LON:NCYT) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their earnings, profitability, dividends, analyst recommendations, valuation, institutional ownership, risk and media sentiment. Do institutionals & insiders have more ownership in CREO or NCYT? 56.1% of Creo Medical Group shares are owned by institutional investors. Comparatively, 0.1% of Novacyt shares are owned by institutional investors. 22.4% of Creo Medical Group shares are owned by insiders. Comparatively, 3.1% of Novacyt shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth. Is CREO or NCYT more profitable? Creo Medical Group has a net margin of -73.93% compared to Novacyt's net margin of -203.06%. Creo Medical Group's return on equity of -41.79% beat Novacyt's return on equity.Company Net Margins Return on Equity Return on Assets Creo Medical Group-73.93% -41.79% -20.09% Novacyt -203.06%-47.73%-27.98% Which has more volatility and risk, CREO or NCYT? Creo Medical Group has a beta of 0.86, meaning that its share price is 14% less volatile than the S&P 500. Comparatively, Novacyt has a beta of -1.86, meaning that its share price is 286% less volatile than the S&P 500. Does the media favor CREO or NCYT? In the previous week, Creo Medical Group had 6 more articles in the media than Novacyt. MarketBeat recorded 6 mentions for Creo Medical Group and 0 mentions for Novacyt. Creo Medical Group's average media sentiment score of 0.26 beat Novacyt's score of 0.00 indicating that Creo Medical Group is being referred to more favorably in the media. Company Overall Sentiment Creo Medical Group Neutral Novacyt Neutral Which has better valuation and earnings, CREO or NCYT? Creo Medical Group has higher revenue and earnings than Novacyt. Creo Medical Group is trading at a lower price-to-earnings ratio than Novacyt, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCreo Medical Group£33.87M1.64-£25.04M-£6.32-2.18Novacyt£18.12M1.60-£36.80M-£54.44-0.77 SummaryCreo Medical Group beats Novacyt on 12 of the 13 factors compared between the two stocks. Get Novacyt News Delivered to You Automatically Sign up to receive the latest news and ratings for NCYT and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NCYT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NCYT vs. The Competition Export to ExcelMetricNovacytMedical Devices IndustryMedical SectorLON ExchangeMarket Cap£28.97M£3.50B£5.74B£3.02BDividend YieldN/A2.44%4.71%5.02%P/E Ratio-0.7775.9528.41160.65Price / Sales1.60100.54419.59278,114.29Price / Cash0.5815.9936.1827.97Price / Book0.423.918.654.70Net Income-£36.80M£132.05M£3.25B£5.90B7 Day Performance4.82%3.86%4.31%0.41%1 Month Performance-2.27%16.66%11.60%7.20%1 Year Performance-15.98%17.49%35.38%70.38% Novacyt Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NCYTNovacytN/AGBX 41.93+1.9%N/A-14.5%£28.97M£18.12M-0.77120CREOCreo Medical GroupN/AGBX 14flatN/A-55.6%£56.60M£33.87M-2.22279News CoverageIUGIntelligent Ultrasound GroupN/AN/AN/AN/A£42.76M£6.57M-18.9165IHCInspiration Healthcare GroupN/AGBX 22.50+4.7%N/A-15.5%£19.49M£42.87M-1.54224High Trading VolumePOLXPolarean ImagingN/AGBX 1.04-0.9%N/A-43.7%£15.28M£5.21M-0.2728AVOAdvanced OncotherapyN/AN/AN/AN/A£9.50MN/A-25.003,900Gap DownRUARUA Life SciencesN/AGBX 11.52-2.0%N/A+4.7%£7.15M£4.05M-2.6848MHCMyHealthCheckedN/AGBX 12.77+2.2%N/A+20.5%£6.65M£9.43M-6.3716Gap UpSUNSurgical Innovations GroupN/AGBX 0.66-6.4%N/A-17.4%£6.11M£12.54M-21.1180MXCTMaxCyteN/AGBX 2.24+6.7%N/A-99.4%£2.96M£57.52M-0.0880High Trading VolumeBELLBelluscuraN/AGBX 0.75flatN/AN/A£1.89M£2.87M-0.0824 Related Companies and Tools Related Companies Creo Medical Group Alternatives Intelligent Ultrasound Group Alternatives Inspiration Healthcare Group Alternatives Polarean Imaging Alternatives Advanced Oncotherapy Alternatives RUA Life Sciences Alternatives MyHealthChecked Alternatives Surgical Innovations Group Alternatives MaxCyte Alternatives Belluscura Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (LON:NCYT) was last updated on 7/27/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredHow to Collect Up To $5,917/mo From Trump’s Made In USA BoomHow to Collect Up To $5,917/mo From Trump's Made In USA Boom Thanks to President Trump's America-First poli...Investors Alley | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Novacyt S.A. Please log in to your account or sign up in order to add this asset to your watchlist. Share Novacyt With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
